文献速递乳房整形与再造显微修复重建

重度肥胖患者微血管乳房再造前的代谢桥接治疗:一项概念验证性风险分析

Metabolic Bridge Therapy before Microvascular Breast Reconstruction in Morbidly Obese Patients: A Proof-of-Concept Risk Analysis.
PubMed 文献 · Plast Reconstr Surg · 2024-10-01

该研究查询2017至2022年体重指数≥35 kg/m²接受减重手术的患者数据库,分析减重手术前后体重指数及肥胖相关合并症变化,并用配对乳房再造风险评估评分评估微血管乳房再造的风险变化。共纳入1026例患者,减重术后1年平均体重指数降至32.7 kg/m²,2型糖尿病缓解率29%,微血管乳房再造30天手术并发症风险从40.4%降至24.8%(P<0.0001)。作者认为代谢桥接治疗对降低肥胖患者微血管乳房再造并发症具有潜在疗效。

要点

  • 减重术后1年平均体重指数由44.7 kg/m²降至32.7 kg/m²,2型糖尿病缓解率29%。
  • 配对风险评估显示微血管乳房再造30天手术并发症从40.4%降至24.8%(P<0.0001)。
  • 术前体重指数每降低1 kg/m²,手术并发症减少3.4%(P<0.0001)。

核心结论

  • 代谢桥接治疗对降低肥胖患者微血管乳房再造并发症具有潜在疗效。

研究设计与样本

  • 查询代谢与减重手术认证与质量改进计划数据库,纳入2017至2022年体重指数≥35 kg/m²接受减重手术的患者。
  • 共纳入1026例患者,平均年龄47岁,平均体重指数44.7 kg/m²。
  • 分析减重手术前及术后1年的体重指数与肥胖相关合并症,并配对分析乳房再造风险评估评分以评估微血管乳房再造的风险变化。

主要发现

  • 合并症包括高血压601例(59%)、2型糖尿病291例(28%)、心血管疾病10例(1%)。
  • 减重术后1年平均体重指数为32.7 kg/m²,2型糖尿病缓解率为29%。
  • 微血管乳房再造配对乳房再造风险评估分析显示,30天手术并发症从减重术前40.4%降至术后24.8%(P<0.0001),绝对风险降低15%,相对风险降低36%,需治疗人数为7。
  • 术前体重指数每降低1 kg/m²,手术并发症减少3.4%(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obese patients experience more complications after autologous breast reconstruction. This study evaluates how bariatric surgery modulates risk of complications in the setting of microvascular breast reconstruction. METHODS: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program databases were queried for patients with body mass index (BMI) greater than or equal to 35 kg/m 2 undergoing bariatric surgery from 2017 to 2022. Outcomes included BMI and obesity-related comorbidities before and 1 year after bariatric surgery. Paired Breast Reconstruction Risk Assessment scores were analyzed to evaluate risk modulation before and after bariatric surgery in the setting of microvascular breast reconstruction. RESULTS: A total of 1026 patients were included with an average age of 47 and BMI of 44.7 kg/m 2 . Comorbidities included hypertension ( n = 601 [59%]), type 2 diabetes ( n = 291 [28%]), and cardiovascular disease ( n = 10 [1%]). One-year outcomes after bariatric surgery included an average BMI of 32.7 kg/m 2 , with remission of type 2 diabetes in 29% of patients. Paired Breast Reconstruction Risk Assessment analysis for microvascular breast reconstruction before and after bariatric surgery showed reduction in 30-day surgical complications (40.4% versus 24.8%; P < 0.0001), with an absolute risk reduction of 15%, a relative risk reduction of 36%, and a number needed to treat of 7. Each 1-kg/m 2 reduction in preoperative BMI was associated with a 3.4% reduction in surgical complications ( P < 0.0001). CONCLUSION: There is potential efficacy for metabolic bridge therapy in reducing complications for obese patients undergoing microvascular breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, IV.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Hammond JB, Tillotson M, Yoon Y, et al. Metabolic Bridge Therapy before Microvascular Breast Reconstruction in Morbidly Obese Patients: A Proof-of-Concept Risk Analysis. Plast Reconstr Surg. 2024. PMID: 39356702. doi:10.1097/PRS.0000000000011797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。